📣 VC round data is live. Check it out!

Nxera Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Nxera Pharma and similar public comparables like Supriya Lifescience, Ironwood Pharmaceuticals, PegBio, Solid Biosciences and more.

Nxera Pharma Overview

About Nxera Pharma

Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).


Founded

1990

HQ

Japan

Employees

181

Website

nxera.life

Financials (LTM)

Revenue: $214M
EBITDA: $1M

EV

$921M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Nxera Pharma Financials

Nxera Pharma reported last 12-month revenue of $214M and EBITDA of $1M.

In the same LTM period, Nxera Pharma generated $1M in EBITDA and had net loss of ($41M).

Revenue (LTM)


Nxera Pharma P&L

In the most recent fiscal year, Nxera Pharma reported revenue of $193M and EBITDA of ($20M).

Nxera Pharma is unprofitable as of last fiscal year, with gross margin of 70%, EBITDA margin of (10%), and net margin of (41%).

See analyst estimates for Nxera Pharma
LTMLast FY202320242025202620272028
Revenue$214M$193M$80M$181M$186M
Gross Profit-$135M$61M$133M$135M
Gross Margin-70%76%74%72%
EBITDA$1M($20M)($36M)$661K($20M)
EBITDA Margin0%(10%)(45%)0%(10%)
EBIT Margin7%(1%)(75%)(19%)(29%)
Net Profit($41M)($79M)($45M)($30M)($79M)
Net Margin(19%)(41%)(56%)(17%)(42%)
Net Debt-$205M---

Financial data powered by Morningstar, Inc.

Nxera Pharma Stock Performance

Nxera Pharma has current market cap of $643M, and enterprise value of $921M.

Market Cap Evolution


Nxera Pharma's stock price is $7.01.

Nxera Pharma share price increased by 15.6% in the last 30 days, and by 22.6% in the last year.

Nxera Pharma has an EPS (earnings per share) of $-0.86.

See more trading valuation data for Nxera Pharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$921M$643M-0.8%15.6%15.2%22.6%$-0.86

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Nxera Pharma Valuation Multiples

Nxera Pharma trades at 4.3x EV/Revenue multiple, and 877.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Nxera Pharma

EV / Revenue (LTM)


Nxera Pharma Financial Valuation Multiples

As of May 27, 2026, Nxera Pharma has market cap of $643M and EV of $921M.

Nxera Pharma has a P/E ratio of (15.9x).

LTMLast FY202320242025202620272028
EV/Revenue4.3x4.8x11.5x5.1x4.9x
EV/EBITDAn/m(47.1x)(25.7x)n/m(47.1x)
EV/EBIT61.3xn/m(15.4x)(27.0x)(17.3x)
EV/Gross Profit-6.8x15.2x6.9x6.8x
P/E(15.9x)(8.2x)(14.2x)(21.1x)(8.2x)
EV/FCF-(44.5x)(23.9x)(15.8x)(44.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Nxera Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Nxera Pharma Margins & Growth Rates

Nxera Pharma grew revenue by 27% but EBITDA decreased by 337% in the last fiscal year.

In the most recent fiscal year, Nxera Pharma reported gross margin of 70%, EBITDA margin of (10%), and net margin of (41%).

See estimated margins and future growth rates for Nxera Pharma

Nxera Pharma Margins

Last FY202420252026202720282029
Gross Margin70%74%72%81%
EBITDA Margin(10%)0%(10%)19%
EBIT Margin(1%)(19%)(29%)17%
Net Margin(41%)(17%)(42%)9%
FCF Margin(11%)(32%)(11%)31%

Nxera Pharma Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth27%126%3%32%
Gross Profit Growth48%120%1%48%
EBITDA Growth(337%)(102%)(3061%)(337%)
EBIT Growth(1887%)(43%)56%(177%)
Net Profit Growth(127%)(33%)159%(127%)
FCF Growth(470%)51%(64%)(470%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Nxera Pharma Operational KPIs

Nxera Pharma's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $1.0M for the same period.

Nxera Pharma's Rule of 40 is 51% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Nxera Pharma's Rule of X is 98% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Nxera Pharma
LTMLast FY202320242025202620272028
Rule of 4015%51%---
Bessemer Rule of X36%98%---
Revenue per Employee-$1.1M---
Opex per Employee-$1.0M---
G&A Expenses to Revenue-50%78%56%51%
R&D Expenses to Revenue41%49%79%41%49%
Opex to Revenue-97%150%92%101%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Nxera Pharma Competitors

Nxera Pharma competitors include Supriya Lifescience, Ironwood Pharmaceuticals, PegBio, Solid Biosciences, Aclaris Therapeutics, Climb Bio, Cormedix, Pharmicell, Zentiva and Immix Biopharma.

Most Nxera Pharma public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Supriya Lifescience7.8x7.0x20.7x20.9x
Ironwood Pharmaceuticals3.5x2.8x7.4x4.9x
PegBio--(19.6x)-
Solid Biosciences--(1.6x)(1.4x)
Aclaris Therapeutics67.2x75.3x(7.1x)-
Climb Bio--(7.7x)(7.5x)
Cormedix1.9x1.9x3.0x3.5x
Pharmicell8.2x7.2x24.7x19.9x

This data is available for Pro users. Sign up to see all Nxera Pharma competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Nxera Pharma

When was Nxera Pharma founded?Nxera Pharma was founded in 1990.
Where is Nxera Pharma headquartered?Nxera Pharma is headquartered in Japan.
How many employees does Nxera Pharma have?As of today, Nxera Pharma has over 181 employees.
Who is the CEO of Nxera Pharma?Nxera Pharma's CEO is Christopher Cargill.
Is Nxera Pharma publicly listed?Yes, Nxera Pharma is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of Nxera Pharma?Nxera Pharma trades under 4565 ticker.
When did Nxera Pharma go public?Nxera Pharma went public in 2004.
Who are competitors of Nxera Pharma?Nxera Pharma main competitors include Supriya Lifescience, Ironwood Pharmaceuticals, PegBio, Solid Biosciences, Aclaris Therapeutics, Climb Bio, Cormedix, Pharmicell, Zentiva, Immix Biopharma.
What is the current market cap of Nxera Pharma?Nxera Pharma's current market cap is $643M.
What is the current revenue of Nxera Pharma?Nxera Pharma's last 12 months revenue is $214M.
What is the current revenue growth of Nxera Pharma?Nxera Pharma revenue growth (NTM/LTM) is 14%.
What is the current EV/Revenue multiple of Nxera Pharma?Current revenue multiple of Nxera Pharma is 4.3x.
What is the current EBITDA of Nxera Pharma?Nxera Pharma's last 12 months EBITDA is $1M.
What is Nxera Pharma's EBITDA margin?Nxera Pharma's last 12 months EBITDA margin is 0%.
What is the current EV/EBITDA multiple of Nxera Pharma?Current EBITDA multiple of Nxera Pharma is 877.6x.
How many companies Nxera Pharma has acquired to date?Nxera Pharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Nxera Pharma has invested to date?Nxera Pharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Nxera Pharma

Lists including Nxera Pharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial